510(k) device
Restrata
Acera Surgical, Inc. · Absorbable Synthetic Wound Dressing (QSZ, Unclassified) · First FDA decision Apr 26, 2017, newest Oct 16, 2026BurnsChronic wounds and ulcers
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
510(k) pathway
Device trials
10
Naming "Restrata"
MAUDE reports
2
Brand "Restrata", since 2015
PubMed studies
8
Mentioning "Restrata"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Restrata
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
- Restrata510(k)
K261245 · Decided Oct 16, 2026 · 183 days after receipt
Device type: Absorbable Synthetic Wound Dressing (QSZ) · General & Plastic Surgery
- Restrata®510(k)
K193583 · Decided Sep 25, 2020 · 277 days after receipt
Device type: Absorbable Synthetic Wound Dressing (QSZ) · General & Plastic Surgery
- Restrata Wound Matrix510(k)
K170300 · Decided Apr 26, 2017 · 85 days after receipt
Device type: Absorbable Synthetic Wound Dressing (QSZ) · General & Plastic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Restrata", any status and sponsor, newest update first.
- Synthetic Electrospun Fiber Matrix in Abdominal Wall Donor Sites for Breast ReconstructionNot yet recruiting
Washington University School of MedicineAcademic, hospital or other
NCT07851415 · 20 participants (planned) · Start Nov 30, 2026 · Primary completion Jan 11, 2028
Device: Restrata® · For: Breast Reconstruction; Deep Inferior Epigastric Perforator; Breast Reconstruction After Mastectomy
Sites: St Louis, Missouri
Acera Surgical, Inc.Not on our public-company list
NCT06578650 · 34 participants (planned) · Start Oct 31, 2024 · Primary completion Aug 2027
Device: Synthetic Electrospun Fiber Matrix · For: Surgical Wound
Sites: Las Vegas, Nevada
Rutgers, The State University of New JerseyAcademic, hospital or other
NCT07316192 · 10 participants (planned) · Start Dec 1, 2025 · Primary completion Sep 2026
Device: Pelashield Painguard · For: Hidradenitis Suppurativa (HS)
Sites: Newark, New Jersey
7 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Restrata", and for the whole product code for context.
This brand
2 reports: 0 malfunction, 2 injury, 0 death
Whole product code QSZ
86 reports: 7 malfunction, 79 injury, 0 death
Newest reports for this brand
- RestrataInjury
3012429393-2026-00001 · Received Sep 15, 2026 · Event dated Aug 19, 2026
Device type: Mesh, Surgical, Absorbable, Plastic And Reconstructive Surgery (OXF)
Device problem as coded: Use of Device Problem
Patient problem as coded: Hypersensitivity/Allergic reaction
ACERA SURGICAL, INC. C/O LINDA BRADDON, PHD
MW5172460 · Received Jul 9, 2025 · Event dated Feb 4, 2025
Device type: Absorbable Synthetic Wound Dressing (QSZ)
Device problem as coded: Material Discolored; Material Erosion; Material Fragmentation; Device Emits Odor; Device Dislodged or Dislocated
Patient problem as coded: Hemorrhage/Blood Loss/Bleeding; Perforation of Vessels; Rupture
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Restrata, Part Number RWM1-2X2Terminated
Z-1030-2022 · Started Mar 21, 2022
Reason given: Misprinted expiration date on the shelf-box
Cause as FDA categorized it: Employee error · Device type: Dressing, Wound, Drug (FRO)
Published research
The most relevant PubMed records for "Restrata"[tiab]. The summary above synthesizes these.
- The Use of a Synthetic Hybrid-Scale Fiber Matrix to Treat Difficult-to-Heal Wounds.
Wilson M · Cureus · 2023
- Advances in Care for Burn and Hypertrophic Scar: Innovations in Prevention and Dermal Regeneration.
Savitz BL, Chennupati V, Alexander O, et al. · Ann Plast Surg · 2025Review, Research Support, Non-U.S. Gov't
- Reconstruction of a Large Cricothyroid Defect Using a Synthetic Hybrid-Scale Fiber Matrix.
Asi K, Tkaczuk A · Laryngoscope · 2025Case Reports
- Soft Tissue Reconstruction With Synthetic Electrospun Fiber Matrix Following Musculoskeletal Injury: A Retrospective Case Series.
Cosgrove C · Eplasty · 2025
- Clinical Application of Bioresorbable, Synthetic, Electrospun Matrix in Wound Healing.
MacEwan M, Jeng L, Kovács T, et al. · Bioengineering (Basel) · 2022
- Efficacy of a Nanofabricated Electrospun Wound Matrix in Treating Full-thickness Cutaneous Wounds in a Porcine Model.
MacEwan MR, MacEwan S, Wright AP, et al. · Wounds · 2018
- What Makes the Optimal Wound Healing Material? A Review of Current Science and Introduction of a Synthetic Nanofabricated Wound Care Scaffold.
MacEwan MR, MacEwan S, Kovacs TR, et al. · Cureus · 2017Review
- A Versatile, Patient-Centred Approach to Surgical Wound Closure: A Single-Centre Case Series on the Use of a Synthetic Electrospun Fibre Matrix in Vasculopathic Patients.
Dudkiewicz M · Int Wound J · 2026
Other devices of this type
Also filed under product code QSZ.
- SiOxD® Wound MatrixSioxmed, LLC · 510(k) 2024
- NovoSorb BTMPolynovo Biomaterials Pty, Ltd. · 510(k) 2025
- HyalomatrixAnika Therapeutics, Inc. · 510(k) 2026
- LUOFUCON® Wound MatrixHuizhou Foryou Medical Devices Co., Ltd. · 510(k) 2026
- Redermo Wound MatrixBeijing Kreate Medical Co., Ltd. · 510(k) 2026
- NovoSorb® MTXPolynovo Biomaterials Pty, Ltd. · 510(k) 2025
- Restrata® MiniMatrixAcera Surgical, Inc. · 510(k) 2023
- NovoSorb MatrixPolynovo Biomaterials Pty, Ltd. · 510(k) 2022
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.